Alphawave Semi and InnoLight Collaborate to Demonstrate Low Latency Linear Pluggable Optics with PCIe 6.0® Subsystem Solution for High-Performance AI Infrastructure at OFC 2024
25.3.2024 16:00:00 EET | Business Wire | Press release
Alphawave Semi (LSE: AWE), a global leader in high-speed connectivity and compute solutions for the world’s technology infrastructure, today announced its collaboration with InnoLight Technology, the leader in data center optics, to bring a low power, low latency linear pluggable optics (LPO) demonstration to OFC 2024. Operating at 64 Gbps per lane, this demonstration showcases Alphawave Semi’s PCIe 6.0® subsystem (Controller + PHY) with InnoLight’s LPO OSFP optics, breaking down barriers to disaggregated networking and enabling connectivity at the datacenter scale. By delivering a complete PCIe 6.0 subsystem featuring Alphawave Semi’s controller IP matched with its industry-leading proven PAM4 SerDes PHY and by collaborating with InnoLight as an industry-leading optics supplier, Alphawave Semi is fostering an ecosystem for accelerating the deployment of optical connectivity and memory coherency solutions, which are essential for scaling AI workloads in next-generation data center infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240325631180/en/
Low Latency Linear Pluggable Optics with PCIe 6.0® Subsystem for High-Performance AI Infrastructure (Graphic: Business Wire)
Osa Mok, Chief Marketing Officer at InnoLight, said, “We are pleased with the collaboration between Alphawave Semi and InnoLight, which demonstrates PCIe 6.0 optical connectivity that offers both low power consumption and low latency, tailored to meet the demanding requirements of high-bandwidth and high-density AI networks. Alphawave Semi’s PAM4 DSP physical layer technology, leveraged with InnoLight’s LPO OSFP, empowers hyperscalers to implement next-generation disaggregated, composable networks.“
Tony Chan Carusone, CTO at Alphawave Semi, said, “We see our collaboration with InnoLight as a significant driver for accelerating the adoption of PCIe technology over optics. The combination of InnoLight’s market-leading optical solution with Alphawave Semi’s robust DSP technology showcases how PCIe technology over optics can enable our customers to massively scale connectivity for their compute and data processing AI workloads.”
Live Demonstration at OFC Exhibit Hall, InnoLight Booth 2625
Attendees can experience a live demonstration of low power, low latency linear pluggable optics (LPO). Operating at 64 Gbps per lane, it showcases Alphawave Semi’s PCIe 6.0 subsystem (Controller + PHY) with InnoLight’s LPO OSFP optics.
More on Alphawave Semi’s PCIe Portfolio: Alphawave Semi’s PCI-Express and CXL Solution
The Alphawave Semi PCIe Controller + PHY subsystem is an extremely power-efficient, low-latency, and highly reliable interface IP, having been built off the industry’s most successful PAM4 SerDes IP. It is available on the most advanced technology nodes. In AI and high-performance computing (HPC) systems where memory performance is key, the Alphawave Semi PCIe 6.0 Subsystem can be expanded to support CXL 3.0 with a PCIe and CXL Controller and enable memory coherency at the data center level.
InnoLight offers a wide range of low power, low latency 400G, 800G, and 1.6T LPO solutions for AI workloads at data center scale, with a silicon photonics platform, with expected capabilities to support PCIe Gen 6 and beyond optical connectivity. InnoLight is also a founding member of LPO-MSA (www.lpo-msa.org), and is actively working with the industry ecosystem to promote wide adoption of LPO solutions for AI networking and computing applications.
PCI-SIG®, PCI Express®, and PCIe ® are registered trademarks and/or service marks of PCI-SIG
About Alphawave Semi
Alphawave Semi is a global leader in high-speed connectivity and compute silicon for the world's technology infrastructure. Faced with the exponential growth of data, Alphawave Semi's technology services a critical need: enabling data to travel faster, more reliably, and with higher performance at lower power. We are a vertically integrated semiconductor company, and our IP, custom silicon, and connectivity products are deployed by global tier-one customers in data centers, compute, networking, AI, 5G, autonomous vehicles, and storage. Founded in 2017 by an expert technical team with a proven track record in licensing semiconductor IP, our mission is to accelerate the critical data infrastructure at the heart of our digital world. To find out more about Alphawave Semi, visit: awavesemi.com.
Alphawave Semi and the Alphawave Semi logo are trademarks of Alphawave IP Group plc. All rights reserved.
About InnoLight Technology
InnoLight is a world leader in providing a wide range of high-speed optical solutions for optical communication networking, especially for AI and Data Center applications, with global footprints in California, Singapore, Thailand, Taiwan, and Suzhou China. For more information, please visit www.innolight.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325631180/en/
Contact information
Gravitate PR for Alphawave Semi
alphawave@gravitatepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom